Diabetes pill shows Real-World promise
NCT ID NCT04862923
Summary
This study observed 336 UK adults with type 2 diabetes who were prescribed the once-daily pill Rybelsus (oral semaglutide) by their doctors. Researchers tracked how well the medication worked in everyday life over 8-10 months, focusing on blood sugar control and weight changes. The goal was to understand the real-world benefits and patient experience with this treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Master Centre for United Kingdom
Gatwick, West Sussex, RH6 0PA, United Kingdom
Conditions
Explore the condition pages connected to this study.